KZR
NASDAQ · Biotechnology
Kezar Life Sciences Inc
$6.20
-0.15 (-2.36%)
Open$6.32
Previous Close$6.35
Day High$6.35
Day Low$6.08
52W High$7.45
52W Low$3.53
Volume—
Avg Volume17.4K
Market Cap46.50M
P/E Ratio—
EPS$-9.69
SectorBiotechnology
Analyst Ratings
Hold
10 analysts
Price Target
+203.4% upside
Current
$6.20
$6.20
Target
$18.81
$18.81
$12.87
$18.81 avg
$22.25
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 16.79M | 17.27M | 15.12M |
| Net Income | 1.29M | 1.30M | 1.12M |
| Profit Margin | 7.7% | 7.5% | 7.4% |
| EBITDA | 2.04M | 2.03M | 1.93M |
| Free Cash Flow | 959.0K | 942.1K | 1.29M |
| Rev Growth | +17.9% | +7.1% | +16.0% |
| Debt/Equity | 0.82 | 0.90 | 0.98 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |